The American biotechnology company Moderna announced that out of 196 participants in its clinical trial infected with Covid-19, no serious form appeared among the group of vaccinated participants, against 30 in the placebo group.
Results which estimate the effectiveness of the vaccine at 94.1%
Two weeks after announcing an efficacy of 94.5% based on preliminary results, Moderna announced that out of 196 participants in its clinical trial who fell ill with Covid-19, 185 were in the placebo group and 11 in the vaccinated group, ie an efficiency reduced to 94.1%.
This means that vaccinated people have seen their risk of contracting Covid-19 reduced by 94% compared to unvaccinated people.
No severe form among vaccinees
“What’s even more exciting and interesting is that in fact we had 30 cases of people who had some form of severe disease, and those 30 people were all on placebo, so no one on the vaccine,” he said. is congratulated Stéphane Bancel, CEO of Moderna, interviewed by BFMTV.
No serious side effect
Moderna said no new serious side effects had been observed in the vaccinated volunteers and that the vaccine had raised “no significant safety concerns”. The most frequently reported side effects were pain around the vaccine injection site, fatigue, body aches and headache.
Towards a Moderna vaccine in December?
Results which prompted the company Moderna to file an application for authorization for emergency use with the American Medicines Agency (FDA), which should convene its advisory committee on vaccines on December 17. In the event of a green light from the FDA, a distribution could take place in the following days. Moderna has also announced that it will apply for a European marketing authorization.
